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In this issue ofCancer Cell, Dudley et al. (2008) report that endothelial cells (ECs) from murine prostate tumors
unexpectedly differentiate into cells with characteristics of bone and cartilage and that human and murine
prostate tumors contain ‘‘calcified’’ ECs. These observations open the possibility for targeted antiangiogenic
therapy.Endothelium is a mesodermal derivative
that codevelops with hematopoietic
stem cells (HSCs) from so-called heman-
gioblasts (Habs) located in the dorsal
aorta (Medvinsky and Dzierzak, 1996)
(Figure 1). A second precursor for endo-
thelium also isolated from the dorsal
aorta, termed mesoangioblasts (Mabs),
generates endothelial cells (ECs) as well
as extravascular mesodermal derivatives
including skeletal muscle, bone, and car-
tilage, but not HSCs (Peault et al., 2007)
(Figure 1). In postnatal life, Mabs with dif-
ferentiation potential similar to fetal Mabs
have been isolated from numerous tis-
sues even though postnatal Mabs gener-
ally express pericyte rather than EC
markers found on fetal Mabs (Peault
et al., 2007). No good evidence exists
that Habs persist postnatally.
In the developing embryo, blood ves-
sels are formed via an initial process of
vasculogenesis followed by remodeling
of the vessels in a process termed angio-
genesis, giving rise to a complex blood
vessel system consisting of arteries,
capillaries, and veins. ECs are specified
depending on the vessel type (vein, artery,
or capillary) to which they belong (Chi
et al., 2003) (Figure 1). Capillaries of the
microvasculature consist essentially of
ECs surrounded by support cells, the
pericytes. ECs found in different capillary
beds are also specified: differences in
structural and functional properties as
well as cell surface antigens and tran-
scriptome have been described for capil-
lary ECs from different organs (Langen-
kamp and Molema, 2008). ECs thus
appear to be highly adapted to the sur-
rounding tissue. Owing to their specifica-
tion, capillary ECs play unique roles inpathological conditions specific to the
organ in which they reside.
New blood vessel formation in postna-
tal life occurs chiefly via angiogenesis.
Only recently has it become apparent
that vasculogenesis, or the recruitment
of EC-restricted progenitors called endo-
thelial progenitor cells (EPCs) to newly
formed vessels, also plays a role in neo-
vascularization (Lyden et al., 2001).
Whether by activation of local postcapil-
lary ECs or maturing EPCs, the initial
event underlying vascularization of (for in-
stance) tumors is the invasion of ECs in
the tumor mass to form primitive vascular
tubes, which then attract pericytes to
generate the surrounding supportive
layer. As is true for ECs present in normal
tissues and organs, the phenotype of
tumor ECs (TECs) varies significantly in
response to the surrounding tumor micro-
environment (Langenkamp and Molema,
2008).
In this issue of Cancer Cell, Dudley and
colleagues (2008) report that ECs isolated
by clonal culture from spontaneously de-
veloping prostate tumors in mice gener-
ate blood vessels in vitro and in vivo in
Matrigel plugs, as expected. Unexpect-
edly, a significant increase in genes and
proteins characteristic of bone and carti-
lage was seen following exposure of the
clonally isolated TECs to osteogenic or
chondrogenic culture conditions, respec-
tively, which was not seen in ECs isolated
from dermis. TECs expressed a number
of typical EC antigens, such as CD31,
VEGFR-2, and vWF, but not others, such
as CD34 and SCA-1. Interestingly, TECs
expressed antigens not found in mature
ECs, such as CD133 and CD90. CD90
was also expressed in mesenchymalCancer Cell 14, Sstem cells (MSCs), but mouse MSCs
also expressed SCA-1. Primary human
and murine prostate tumors often con-
tained areas of calcification. The authors
found that approximately 4% of CD31+
human prostate tumor blood vessels
were positive for von Kossa staining,
which detects areas of high concentra-
tions of inorganic phosphate typical of
calcification. Although calcification has
been observed in vessel walls, it usually
is located in the smooth muscle layer sur-
rounding arteries and not at the luminal
side of vessels.
As discussed above, ECs are highly
adaptable, and their phenotype can be
influenced by the tumor environment.
The osteogenic tumor microenvironment
typical for prostate cancer could therefore
be responsible for the calcification ob-
served in prostate TECs. However, ECs
are lineage restricted and do not normally
generate other mesodermal cell types.
So, what is the mechanism underlying
this novel observation?
One possibility is that cells recruited to
the vascular bed of (prostate) tumors are
not EC-restricted EPCs but cells with
a broader differentiation ability, such as
Mabs, among others (Figure 1). Aside
from Mabs, a number of other, perhaps
related, cell populations have been iso-
lated from muscle that have the ability to
generate not only skeletal myoblasts but
other extravascular mesodermal cells
and endothelium, including culture-iso-
lated muscle-derived stem cells (MDSCs)
(Peault et al., 2007) and prospectively iso-
lated myoendothelial cells (Peault et al.,
2007). Moreover, a number of cell popula-
tions have been isolated from cultured
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into endothelial cells, aside
from cells with not only meso-
dermal but also endodermal
or ectodermal features (Sera-
fini and Verfaillie, 2006). The
role of these cells in neo-
vascularization processes is
unknown even though many
of these non-EC-restricted
stem/progenitor cells contrib-
ute to some degree to vessel
formation in ischemic lesions
or tumors when administered
exogenously. As Dudley et al.
(2008) have done, one could
determine whether the TECs
have antigenic determinants
in common with any of these
cell populations. However,
the ability of ECs to adapt to
their environment is exempli-
fied by the ease with which
they adapt themselves to cul-
ture conditions. Because of
this context-dependent ad-
aptation, in vitro-cultivated
ECs may not fully reflect the
antigenic determinants found
in vivo (Langenkamp and
Molema, 2008).
Another possibility, also
suggested by the authors, is
that under certain circum-
stances such as the presence
of tumor cells, ECs can acquire unex-
pected differentiation potential. Recent
studies have suggested that for a number
of epithelial tumors, genetic mutations
lead to the reacquisition of features of
stem cells by progenitor or precursor
cells, a process referred to as dedifferen-
tiation (Kasper, 2008). Moreover, in the
era of induced pluripotent stem cells, it
has become obvious that a differentiated
state can, at least in vitro, be changed to
a more multi/pluripotent state (Takahashi
et al., 2007). One could hence speculate
that the ability of TECs to differentiate at
least to some extent into cells with osteo-
genic and chondrogenic properties has
been evoked by the tumor microenviron-
ment, leading to the reacquisition of
a more broad mesodermal fate (Figure 1).
Direct transdifferentiation, without the
acquisition of a more primitive state, has
been described for a number of types of
cells, including MSCs and cells in the
pancreas, among others (Caplan, 1991;
Lardon et al., 2004). It is therefore also
possible that some TECs undergo direct
transdifferentiation from an EC to an
MSC-like cell (Figure 1). Another possibil-
ity is that clonally derived, cultured TECs
have been dedifferentiated by the culture
process and therefore have acquired
broader potential, as might be the case
for some of the non-EC-restricted cells
capable of generating endothelium as dis-
cussed above (Serafini and Verfaillie,
2006). The in vitro studies compared
TECs from prostate with capillary ECs
from dermis; thus, the difference in the
microvascular bed from which the cells
were selected could also play a role in
the differences in phenotype and/or dif-
ferentiation potential of the ECs. How-
ever, as CD31+ cells in capillaries in pri-
mary prostate tumor samples contain
inorganic phosphate, as shown by the
von Kossa staining, the ability of CD31+
cells to produce calcified de-
posits is not merely a charac-
teristic acquired in vitro.
It will be of interest to study
tumor vasculature in other
types of tumors to determine
whether TECs can adapt
themselves to the tumor envi-
ronment by acquiring some
of the characteristics of that
specific environment. Such
specification may ultimately
allowone to specifically target
the TECs, but not normal ECs,
to treat tumors. The question
of whether this represents a
spontaneous in vivo dediffer-
entiation or the recruitment
of non-EC-restricted stem/
progenitor cells as a source
of TECs can only be resolved
by clever lineage-tracing
experiments.
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Figure 1. Possible Mechanisms Underlying the Apparent
Osteogenic Differentiation of Tumor Endothelial Cells
Endothelial cells (ECs) are derived from mesoderm (Meso) and may appear
from either a common endothelial/hematopoietic progenitor, termed heman-
gioblasts (Habs), or another endothelial/extravascular mesodermal progenitor,
termed mesoangioblasts (Mabs), both present in the floor of the aorta. Via
asymmetric divisions, the two common progenitors would give rise to hemato-
poietic stem cells (HSCs) and mesenchymal stem cells (MSCs), respectively,
plus endothelial progenitor cells (EPCs). EPCs differentiate into ECs that are
specified depending on the blood vessels to which they populate: arterial
ECs (aECs), venous ECs (vECs), or capillary ECs (cECs). cECs are further
specified depending on the microvascular network they belong to. Dudley
et al. (2008) have identified tumor endothelial cells (TECs) that can differentiate
into cells with osteogenic and chondrogenic characteristics. This may reflect
the recruitment of endothelial/extravascular mesodermal progenitors to the
tumor vascular bed, tumor-mediated dedifferentiation of cECs into cells
that have endothelial/extravascular mesodermal characteristics, or trans-
differentiation between ECs and MSC-like cells. ICM, inner cell mass; ME,
mesendoderm.194 Cancer Cell 14, September 9, 2008 ª2008 Elsevier Inc.
